TemozolomideThird Party Manufacturing in India

Temozolomide is an orally bioavailable prodrug that undergoes rapid chemical conversion at physiological pH to its active metabolite, MTIC. Unlike many alkylating agents that require hepatic metabolic activation, temozolomide undergoes spontaneous hydrolysis in the bloodstream and tissues, making its activation independent of liver enzyme function. MTIC then decomposes to generate a methyldiazonium cation, which acts as a potent alkylating species. The primary site of DNA methylation is the O⁶ position of guanine residues, forming O⁶-methylguanine adducts. During DNA replication, these modified guanine bases mispair with thymine instead of cytosine, triggering the DNA mismatch repair system. The mismatch repair machinery attempts to excise the damaged base, but the persistent O⁶-methylguanine adducts lead to futile cycles of DNA repair that ultimately result in double-strand breaks and cell death. The cytotoxicity of temozolomide is modulated by the DNA repair enzyme O⁶-methylguanine-DNA methyltransferase, which directly removes the methyl group from the O⁶ position of guanine, restoring the undamaged base. High levels of MGMT activity in tumour cells are associated with resistance to temozolomide. Temozolomide also produces minor lesions at the N⁷ position of guanine and N³ position of adenine, though these are less cytotoxic. The drug penetrates the blood-brain barrier effectively, achieving cerebrospinal fluid concentrations approximately 20% of plasma levels, making it particularly valuable for the treatment of brain tumours. Temozolomide is cell cycle phase-nonspecific but shows greatest activity during S-phase.

Therapeutic Uses

Temozolomide is prescribed for the treatment of:

• Glioblastoma Multiforme: Approved as first-line treatment in combination with radiotherapy for newly diagnosed glioblastoma, followed by maintenance therapy. This regimen has significantly improved survival outcomes.
• Anaplastic Astrocytoma: Approved for the treatment of refractory anaplastic astrocytoma in patients who have progressed following standard therapy.
• Neuroendocrine Tumours: Used in protocols for advanced or progressive neuroendocrine tumours, particularly pancreatic neuroendocrine tumours.
• Adrenal Gland Cancer: Employed in combination regimens for adrenocortical carcinoma.
• Small Cell Lung Cancer: Investigated and used in combination protocols for relapsed small cell lung cancer.

Why Manufacturers Choose Temozolomide

Temozolomide is a high-value oncology drug with strong demand driven by its position as the standard of care for glioblastoma, the most common primary malignant brain tumour. The lyophilised injection formulation requires specialised aseptic processing capabilities, while the oral capsule form offers an alternative presentation. The blood-brain barrier penetration makes temozolomide unique among alkylating agents and ensures its continued clinical relevance. Indian manufacturers with WHO-GMP certified lyophilisation infrastructure and cytotoxic handling capabilities are well-positioned to serve both domestic hospital supply and export markets. The API is produced through a well-established synthetic pathway, with multiple qualified suppliers ensuring raw material security. Temozolomide is listed on the WHO Essential Medicines List.

This makes Temozolomide one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.